Traveling Exhibit of Cancer Educational Resources

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 6
Volume 6
Issue 6

ROCHESTER, NY--The WHO International Network for Cancer Education (INCE) has joined with its first partner, the American Association for Cancer Education (AACE), to put together an international traveling exhibit of educational materials and resources for cancer education, to be shown at many of the smaller cancer congresses around the world, Charles D. Sherman, Jr., MD, told Oncology News International.

ROCHESTER, NY--The WHO International Network for Cancer Education (INCE)has joined with its first partner, the American Association for CancerEducation (AACE), to put together an international traveling exhibit ofeducational materials and resources for cancer education, to be shown atmany of the smaller cancer congresses around the world, Charles D. Sherman,Jr., MD, told Oncology News International.

Dr. Sherman is director of the Highland Hospital Cancer Treatment Center,Rochester, NY, and co-director of INCE, along with Richard R. Love, MD,of the University of Wisconsin, Madison.

The INCE expects the initial collection to be exhibited at the AACEmeeting in Atlanta next October; it then will be reviewed and refined fordisplay elsewhere. An offshoot of this project is the production of anInternational Directory of materials and resources for cancer education,as well as individuals and organizations involved in cancer education.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content